Growth hormone and respiratory compromise in Prader-Willi Syndrome.
Recombinant human growth hormone (rhGH) therapy in Prader-Willi syndrome (PWS) causes increased basal metabolic rate and oxygen consumption, and hence increased ventilatory load. The case of an adolescent with PWS who experienced respiratory deterioration with an increase in rhGH and improvement with cessation of therapy is reported.
Wilson
S S I
SS
Department of Respiratory and Sleep Medicine, Mater Children's Hospital, South Brisbane, Australia.
Cotterill
A M
AM
Harris
M-A
MA
D000293:Adolescent; D019382:Human Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D017286:Polysomnography; D011218:Prader-Willi Syndrome / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000139:chemically induced*
D011994:Recombinant Proteins; D019382:Human Growth Hormone